CORE Biomedicine
Develops novel cancer therapeutics, backed by venture financing and an AMED grant to advance its oncology pipeline.
Overview
CORE Biomedicine is advancing novel cancer therapeutics for the oncology market. The company’s disclosed focus is on developing treatments intended to address cancer, though specific modalities, targets, or clinical-stage details were not provided. The company raised $21 million in Series A venture financing and also received an AMED grant award. That combination of venture capital and grant support provides funding context for its therapeutic development plans and distinguishes the round in the available disclosure.
Funding History
CORE Biomedicine Secures $21 Million Series A Venture Financing and Receives AMED Grant Award to Advance Novel Cancer Therapeutics
Frequently Asked Questions
- How much funding does AI Funding track for CORE Biomedicine?
- AI Funding tracks $21M for CORE Biomedicine across 1 funding round in this database.
- What does CORE Biomedicine do?
- CORE Biomedicine is advancing novel cancer therapeutics for the oncology market. The company’s disclosed focus is on developing treatments intended to address cancer, though specific modalities, targets, or clinical-stage details were not provided. The company raised $21 million in Series A venture financing and also received an AMED grant award. That combination of venture capital and grant support provides funding context for its therapeutic development plans and distinguishes the round in the available disclosure.
- Where is CORE Biomedicine headquartered?
- CORE Biomedicine is headquartered in San Francisco, CA.
Related Insights
Compare the leading AI-focused VC firms: Andreessen Horowitz, Sequoia Capital, Thrive Capital, and 7 more. Analysis of 150+ AI deals, investment strategies, sector focus, and portfolio performance.
Track 395+ AI funding rounds—investors, valuations, and deal sizes from pre-seed to IPO. Updated daily so you never miss a round.
An in-depth look at how AI-focused venture capital operates — from fund structure and deal sourcing to due diligence, portfolio management, and exit strategies in the AI era.